Evaluating the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and Telmisartan/Amlodipine

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 131 participants.

Also called NCT04158076

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 131 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04158076
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04158076. Randomized; double masking; primary purpose treatment. Start 2020-01-23 (actual); primary completion 2021-01-14 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluating the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and Telmisartan/Amlodipine
Condition
Hypercholesterolemia
Condition
Hypertension
Intervention (Drug)
Ezetimibe/Rosuvastatin
Intervention (Drug)
Telmisartan
Intervention (Drug)
Telmisartan/Amlodipine 80 Mg-5 Mg ORAL TABLET
Lead sponsor
Addpharma Inc. (class: industry)

Record details

Record id
cardio:ct-nct04158076
Content hash
8d15419e5d11aa46b3fba65ab660506fdf3706b4a3e149a10435301e3fa92907